WO1990009188A1 - In ovo administration of growth factors alters physiological development and response of poultry - Google Patents
In ovo administration of growth factors alters physiological development and response of poultry Download PDFInfo
- Publication number
- WO1990009188A1 WO1990009188A1 PCT/US1989/005131 US8905131W WO9009188A1 WO 1990009188 A1 WO1990009188 A1 WO 1990009188A1 US 8905131 W US8905131 W US 8905131W WO 9009188 A1 WO9009188 A1 WO 9009188A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- eggs
- poultry
- day
- growth
- growth factor
- Prior art date
Links
- 244000144977 poultry Species 0.000 title claims abstract description 40
- 230000004044 response Effects 0.000 title claims abstract description 21
- 238000011161 development Methods 0.000 title claims abstract description 16
- 239000003102 growth factor Substances 0.000 title claims description 33
- 235000013601 eggs Nutrition 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 45
- 241000287828 Gallus gallus Species 0.000 claims description 70
- 235000013594 poultry meat Nutrition 0.000 claims description 35
- 238000002347 injection Methods 0.000 claims description 27
- 239000007924 injection Substances 0.000 claims description 27
- 238000011534 incubation Methods 0.000 claims description 22
- 230000012010 growth Effects 0.000 claims description 19
- 239000000122 growth hormone Substances 0.000 claims description 19
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical group CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 18
- 229940039009 isoproterenol Drugs 0.000 claims description 18
- 108010051696 Growth Hormone Proteins 0.000 claims description 15
- 102000018997 Growth Hormone Human genes 0.000 claims description 15
- 235000013330 chicken meat Nutrition 0.000 claims description 14
- 102000009027 Albumins Human genes 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 9
- 239000000808 adrenergic beta-agonist Substances 0.000 claims description 9
- 235000013372 meat Nutrition 0.000 claims description 9
- 241000286209 Phasianidae Species 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 229940036555 thyroid hormone Drugs 0.000 claims description 8
- 239000005495 thyroid hormone Substances 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 5
- 108010006025 bovine growth hormone Proteins 0.000 claims 1
- 230000018109 developmental process Effects 0.000 abstract description 14
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 230000012447 hatching Effects 0.000 abstract description 4
- 230000037396 body weight Effects 0.000 description 35
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 31
- 230000000694 effects Effects 0.000 description 31
- 238000011282 treatment Methods 0.000 description 26
- 241000271566 Aves Species 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 25
- 210000001789 adipocyte Anatomy 0.000 description 22
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 18
- 230000004130 lipolysis Effects 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000000577 adipose tissue Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000002366 lipolytic effect Effects 0.000 description 10
- 102000009016 Cholera Toxin Human genes 0.000 description 9
- 108010049048 Cholera Toxin Proteins 0.000 description 9
- 210000000579 abdominal fat Anatomy 0.000 description 9
- 229960000278 theophylline Drugs 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 5
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000012488 skeletal system development Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 235000019754 Grower Diet Nutrition 0.000 description 3
- 235000019755 Starter Diet Nutrition 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000006054 starter diet Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 208000015580 Increased body weight Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 230000011759 adipose tissue development Effects 0.000 description 2
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000007630 basic procedure Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 239000006055 grower diet Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000006461 physiological response Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101001075376 Bos taurus Gamma-glutamyl hydrolase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 229960005263 bucladesine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000031070 response to heat Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Definitions
- the present invention relates to the production of meat producing poultry. It further relates to the in ovo introduction of biologically active substances into the fertile eggs of the poultry to manipulate physiological development and response of the poultry after hatching.
- the object of this invention is to provide a less expensive and more efficient and effective method of producing better poultry.
- This invention meets this goal by providing for a simple process of in ovo manipulation of the physiological development and response of the poultry.
- the method involves the introduction of various growth factors into the incubating fertilized eggs.
- the altered poultry are allowed to hatch and mature. This results in altered growth, development and physiological responses in the maturing poultry without further
- the invention further provides for a product, poultry, which have been altered by in ovo introduction of growth factors. More specifically, the invention provides for a method of enhancing the growth and meat production of poultry by injecting fertilized poultry eggs, particularly chickens or turkeys, with a growth factor. Specific growth factors which may be injected include, but are not limited to, bovine, ovine or porcine growth factor, thyroid hormones (i.e. T 3 and T 4 ) and isoproterenol.
- the eggs be injected during the time period from and including the first day of the second half of the incubation period up to and including the day the eggs are transferred from the incubator to the hatcher. More specifically, it provides that the eggs be injected on the first day of said time period or on the day the eggs are transferred to the hatchery.
- the physiologically altered poultry are then allowed to hatch and mature.
- the invention further provides for the optional step of administering a beta-adrenergic agonist to the maturing poultry to enhance or trigger the altered physiological development and response.
- the invention provides for a method of enhancing the growth and meat production of poultry by injecting an effective amount of ovine growth hormone or thyroid hormone into the albumin of incubating fertilized chicken eggs.
- the eggs are injected on the first day of the second half of the incubation period of the eggs.
- the altered poultry is allowed to hatch and mature.
- Isoproterenol may then be fed to the altered poultry to enhance or trigger certain altered characteristics.
- Figure 1 shows the effect of in ovo injection of oGH on shank length of broilers at 7 weeks of age. As the figure indicates, shank length increased significantly in males treated with either 2.5 or 250 ⁇ g of oGH.
- Figure 2 shows the adipocyte volume distribution at 7 weeks of age following in ovo oGH administration. Both male and female broilers treated with 250 ⁇ g oGH possessed higher percentages of large volume adipocytes than the controls.
- Figure 3 shows the effect of in ovo injections of oGH on subsequently induced lipolysis of adipocytes in vitro. Lipolysis was measured as a function of glycerol release. The data indicate that oGH inhibits lipolysis by
- Figure 4 shows the effect of in ovo injection of T 4 and T 3 and feeding of isoproterenol on body weights of male broilers. The data indicates that T 3 increased male body weight over the control and that T 4 decreased body weight compared to the control.
- Figure 5 shows the effect of in ovo injection of T 4 and T 3 and feeding of isoproterenol on body weights of female broilers. The data indicates that T 3 increased body weight through week 4 and that after week 4 both T 3 and T 4 decreased body weight compared to the control.
- Figure 6 shows the effect of in ovo injection of T 4 and T 3 and feeding of isoproterenol on carcass protein composition. The data indicates that T 3 produced a significant increase in protein content in male broilers compared to controls.
- Figure 7 shows the effect of in ovo injection of T 4 and T 3 and feeding of isoproterenol on carcass fat percentage. The data indicates that T 3 tends to decrease carcass fat compared to controls.
- Figure 8 shows the effect of in ovo injection of T 4 and T 3 and feeding of isoproterenol on abdominal fat pad weight as a percentage of body weight.
- the data indicates that T 4 decreased percentage of fat pad weight compared to controls.
- the discussion and examples which follow detail the best known method for performing the invention.
- the method provides for the introduction of biologically active substances into the eggs of poultry to alter the physiological development and responses of the hatched birds. This method may be used for all poultry (i.e. domesticated birds kept for eggs or meat), including chickens and turkeys.
- the in ovo manipulation can cause many desired changes in the physiological development and response of maturing birds after hatching. Some of these effects appear to be sex dependent. Growth factors can increase body weight, skeletal development and feed efficiency. This is especially notable with the use of mammalian growth hormones. Growth factors also affect adipose tissue development, altering both the size of adipose cells and the lipolytic responsiveness of such cells.
- the growth factors which may be utilized are various substances which affect the growth and development of tissue, and which affect physiological responses.
- the preferred growth factors are growth hormones and the thyroid hormones, T 3 and T 4 .
- the most preferred growth hormones are mammalian hormones, particularly ovine and bovine.
- Other possible growth factors include, but are not limited to other hormones (e.g. androgens), various steroids, and beta-adrenergic agonists such as
- isoproterenol The amount of growth factor used depends upon the type and size of the egg, the species of poultry, and the type of growth factor used. For example, a range of 2.5 ⁇ g to 250 ⁇ g of growth homone is preferred for broilers with 250 ⁇ g most preferred, but 375 ⁇ g were administered to turkeys. For the thyroid hormones, the preferred amount for administration to broilers is .01 ⁇ g of T 3 and 1.0 ⁇ g of T 4 . The preferred dosage was chosen because the amount is biologically effective and results in the highest rate of hatchability. These examples are not intended to limit the amounts of growth factor which may be used.
- the growth factors are introduced into the eggs of the poultry during incubation.
- the growth factor may be introduced into the albumin or onto the chorioallantoic membrane.
- site of introduction may also impact the necessary dosage. It is believed, although the inventors are not limited to this theory, that a smaller dosage will be effective if introduced onto the membrane.
- the preferred method of introduction is injection, although other methods such as spraying or dipping may be used if the growth factor is of sufficiently small size.
- the preferred time window for injection is from and including the first day of the second half of the
- the incubation period up to and including the day of transfer from the incubator to the hatcher e.g. days 11 to 18 for broilers. This does preclude the injection of growth factor earlier in the incubation period.
- the incubation period is the time period from the day the eggs are placed in the incubator until they hatch. This includes the time period the eggs are in the hatcher. It is believed that the day the eggs are transferred from the incubator to the hatcher will be the most efficient day for introduction of the growth factor. Additionally, it appears that the hatchability rate is higher when the eggs are injected later in the incubation period.
- later introduction of growth factors may be more effective as certain tissues mature and become more active. For example, growth hormones may have a greater effect on body weight when injected after day 17 of the broiler
- a preferred class of additives is the beta-adrenergic agonists, in particular isoproterenol. While these compounds are characterized as food additives it is not precluded that they could be administered to the birds in a different fashion.
- time period of administration and the amounts used may differ depending on the size and needs of the poultry species and the desired result.
- Example 1 The affect of in ovo administration of growth hormone on broiler chickens. Administration of Growth Hormone
- Chicks from both trials were wingbanded, weighed and sexed. Chicks were randomly assigned to floor pens according to sex and treatment. Birds were fed diets ad libitum. From 0 to 3 weeks of age the birds were fed a 22% protein, 3125 kcal energy starter diet. From 3 to 7 weeks of age the birds were fed a 19% protein, 3284 kcal energy grower ration. Body weight and feed consumption were recorded weekly. Shank length was measured at 3, 5 and 7 weeks of age.
- Carcass Composition Birds chosen for carcass analysis were sacrificed by cervical dislocation at 7 weeks. Fat pad weights were recorded. Frozen carcasses (including feathers) were ground twice in a commercial meat grinder to obtain an homogenous mixture. Carcass fat content was determined by ether extraction and protein content was determined by the Kjedahl method. Methods of Analysis, Association of
- a sample of the fat pad of the broilers used for carcass analysis was obtained for adipose cellularity studies. Cells were prepared for sizing and counting by a modification of the procedure of Hirsh and Gallain, J. Lipid Res. 9:110-119 (1968).
- a 50-100mg sample of each fat pad was immediately placed in a 3% osmium tetroxide solution: 1.5 ml of 50 mM collidine, pH 7.4 plus 2.5 ml of 3% osmium tetroxide (diluted in the collidine buffer) for 72 hrs at 41°C for fixation. Following fixation, samples were washed with 0.9% saline (pH 7.4).
- Adipocytes were then separated into two cell size ranges by sequential filtration through 240, 64 and 25 micron nylon screens. Debris collected on the 240 micron screen was discarded. Cells were washed from the remaining screens with 0.1% Triton X-100 in saline, pH 10. Cell size and number were determined by use of an electronic particle counter (Coulter Electronics, Inc., Model ZM) and channelizer (Coulter Electronics, Inc., Model C256). A 0.5 ml sample of the continuously stirring cell suspension was aspirated through a 400 micron aperature tube for cell sizing and counting.
- the distribution of cell diameters was calculated by totalling the sum of each 10-micron increment of cell sizes. Cell number was calculated using the specific density of fat (0.901) and the average cell volume. Average cell diameters and volumes were calculated using the standard geometrical formulas for a sphere.
- Adipocytes were isolated from the abdominal fat pads of 7-week old broilers by a modification of the procedure of Rodbell, J. Biol. Chem. 239:375-380 (1964). Adipose tissue was placed in warmed, oxygenated Krebs-Ringer bicarbonate buffer (KRB) containing 0.1% collagenase (Sigma, lot 126F-6735), 4% albumin and 1 mM glucose for approximately 45 min in a shaking waterbath at 41°C.
- KRB oxygenated Krebs-Ringer bicarbonate buffer
- samples were gently agitated using wide-mouthed siliconized pasteur pipettes to mechanically disrupt clumps of connective tissue. Following enzymatic disruption of the tissue, the samples were washed 3x in the above KRB solution, collagenase-free. Samples were then filtered through a 240 micron nylon-mesh filter and counted as previously. Dilutions of 3.0 x 10 cells/ml were made and 0.5 ml of the cell suspension was added to 0.5 ml of warmed KRB buffer. Fifty microliters of buffer containing each lipolytic compound at specified concentrations were added to the appropriate culture tubes.
- Table 1 Effect of in ovo ovine growth hormone injection on body weight (gms) and cumulative feed conversion ratios of male broilers from 1 to 7 weeks of age.
- Feed to gain ratio determinations were made on the broilers. Male broilers injected with oGH exhibited significantly improved feed conversion ratios from hatch to 3 weeks of age. No difference in feed to gain ratios was observed during the 4-7 week period. (Table 1). The feed to gain ratio in female broilers was not
- Adipose cellularity data on selected broilers suggested that in ovo oGH administration altered adipose tissue development. Both male and female broilers treated with 250 ⁇ g of oGH exhibited larger adipocytes with a corresponding decrease in the number of cells per gram tissue, as determined at 7 weeks of age. (Table 5).
- adipocyte cell size suggests a decrease in lipolysis. Studies were done to determine if lypolysis is effected by in ovo injection of oGH, and if so how.
- cholera toxin imparts adenylate cyclase through a receptor-independent
- adipocytes exhibited decreased sensitivity to cholera toxin or theophylline-induced lipolysis and increased lipolytic response to dcAMP in vitro, suggesting that oGH injected in ovo decreased lipolysis either by diminishing adenylate cyclase activity or enhancing phosphodiesterase activity.
- the combined addition of cholera toxin and theophylline significantly improved the lipolytic response over that of the addition of either compound alone, further implicating high phosphodiesterase activity in adipocytes of broilers injected with oGH in ovo.
- Example 2 Determination of Growth and Skeletal
- Treatment means ⁇ SEM significantly (P>.05) differ within ages if superscripts differ.
- Example 3 Summary of Trials Examining the Effects of In Ovo GH Administration on Seven Week Body Weights of Broilers.
- Table 9 Effect of in ovo ovine growth hormone injection on body weight (gms of turkeys from hatch of 10 weeks of age.
- Body weights and feed consumption were recorded weekly and at 35 and 49 days of age adipocytes were isolated from abdominal fat pads by a modification of the method of Rodbell (1964). Fat pads from four birds per in ovo treatment were excised and rinsed in warm 0.9% saline (pH 7.4) to remove free lipid droplets. Fat tissue was then minced and a 4 gram sample from each in ovo treatment group placed into Kreb's Ringer bicarbonate buffer containing 0.1%
- adipocytes isolated from both control and T 3 -treated birds resulted in significant increases in glycerol release at both 35 and 49 days (Table 11).
- Glycerol release was significantly greater in response to 10 mM dcAMP in cells from T 3 -treated birds as compared to controls (Table 11).
- No significant differences in glycerol release in response to cholera toxin were observed between control of T 3 -treated birds at 35 or 49 days of age (Table 12).
- Example 6 The effect of in ovo injection of thyroid hormone and feeding of dietary betaadrenergic agonist on broiler chickens.
- Feed consumption and body weights were recorded weekly throughout the grow-out trial.
- 10 randomly selected birds from each in ovo treatment group and sex were selected at 8 weeks of age and killed via cervical dislocation.
- Abdominal fat pads were removed and weighed and a sample was taken for cellularity studies.
- Carcasses were frozen at -20°C for subsequent carcass analysis. (See Example 1 and 5 for basic procedures).
- T 3 -treated females exhibited significantly greater body weights than T 4 -treated birds at week one.
- body weights of T 4 -treated females were significantly less than weights of control females.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a procedure for the in ovo introduction of biologically active compounds into fertile eggs of poultry to manipulate the physiological development and response of the birds after hatching.
Description
IN OVO ADMINISTRATION OF GROWTH FACTORS
ALTERS PHYSIOLOGICAL DEVELOPMENT AND RESPONSE OF POULTRY
The present invention relates to the production of meat producing poultry. It further relates to the in ovo introduction of biologically active substances into the fertile eggs of the poultry to manipulate physiological development and response of the poultry after hatching.
It further relates to the use of certain food additives to trigger or enhance certain altered characteristics in the maturing poultry. As part of an effort to increase the human food supply, investigators have explored numerous means of manipulating tissue development in commercial meat producing animals. Most of the work has centered on genetic manipulation, nutrition therapy and pharmaceutical
therapy. These teachings have been somewhat successful but they present various problems.
For example, genetic selection programs for improved growth rates in chickens have led to the development of increasingly fat broiler stocks. Excessive lipid
deposition results in increased production costs for the broiler producer as well as poor consumer acceptability of the broiler product. Nutritional and pharmaceutical therapy of hatched chickens is extremely labor and capital intensive and is often unsuccessful.
The object of this invention is to provide a less expensive and more efficient and effective method of producing better poultry. This invention meets this goal by providing for a simple process of in ovo manipulation of the physiological development and response of the poultry. The method involves the introduction of various growth factors into the incubating fertilized eggs. The altered poultry are allowed to hatch and mature. This results in altered growth, development and physiological responses in the maturing poultry without further
treatment with the growth factors. Some of these altered characteristics of the maturing poultry may be triggered or enhanced by administering to the poultry a betaadrenergic agonist and this invention further provides for this production step. The invention further provides for a product, poultry, which have been altered by in ovo introduction of growth factors. More specifically, the invention provides for a method of enhancing the growth and meat production of poultry by injecting fertilized poultry eggs, particularly chickens or turkeys, with a growth factor. Specific growth factors which may be injected include, but are not limited to, bovine, ovine or porcine growth factor, thyroid hormones (i.e. T3 and T4) and isoproterenol. It further provides that the eggs be injected during the time period from and including the first day of the second half of the incubation period up to and including the day the eggs are transferred from the incubator to the hatcher. More specifically, it provides that the eggs be injected
on the first day of said time period or on the day the eggs are transferred to the hatchery. The physiologically altered poultry are then allowed to hatch and mature. The invention further provides for the optional step of administering a beta-adrenergic agonist to the maturing poultry to enhance or trigger the altered physiological development and response.
Most specifically, the invention provides for a method of enhancing the growth and meat production of poultry by injecting an effective amount of ovine growth hormone or thyroid hormone into the albumin of incubating fertilized chicken eggs. The eggs are injected on the first day of the second half of the incubation period of the eggs. Thereafter, the altered poultry is allowed to hatch and mature. Isoproterenol may then be fed to the altered poultry to enhance or trigger certain altered characteristics. Figure 1 shows the effect of in ovo injection of oGH on shank length of broilers at 7 weeks of age. As the figure indicates, shank length increased significantly in males treated with either 2.5 or 250 μg of oGH. Figure 2 shows the adipocyte volume distribution at 7 weeks of age following in ovo oGH administration. Both male and female broilers treated with 250 μg oGH possessed higher percentages of large volume adipocytes than the controls.
Figure 3 shows the effect of in ovo injections of oGH on subsequently induced lipolysis of adipocytes in vitro. Lipolysis was measured as a function of glycerol release. The data indicate that oGH inhibits lipolysis by
increasing phosphodiesterase activity.
Figure 4 shows the effect of in ovo injection of T4 and T3 and feeding of isoproterenol on body weights of male broilers. The data indicates that T3 increased male body weight over the control and that T4 decreased body weight compared to the control.
Figure 5 shows the effect of in ovo injection of T4 and T3 and feeding of isoproterenol on body weights of female broilers. The data indicates that T3 increased body weight through week 4 and that after week 4 both T3 and T4 decreased body weight compared to the control.
Figure 6 shows the effect of in ovo injection of T4 and T3 and feeding of isoproterenol on carcass protein composition. The data indicates that T3 produced a significant increase in protein content in male broilers compared to controls.
Figure 7 shows the effect of in ovo injection of T4 and T3 and feeding of isoproterenol on carcass fat percentage. The data indicates that T3 tends to decrease carcass fat compared to controls.
Figure 8 shows the effect of in ovo injection of T4 and T3 and feeding of isoproterenol on abdominal fat pad weight as a percentage of body weight. The data indicates that T4 decreased percentage of fat pad weight compared to controls. The discussion and examples which follow detail the best known method for performing the invention. The method provides for the introduction of biologically active substances into the eggs of poultry to alter the physiological development and responses of the hatched birds. This method may be used for all poultry (i.e.
domesticated birds kept for eggs or meat), including chickens and turkeys.
The in ovo manipulation can cause many desired changes in the physiological development and response of maturing birds after hatching. Some of these effects appear to be sex dependent. Growth factors can increase body weight, skeletal development and feed efficiency. This is especially notable with the use of mammalian growth hormones. Growth factors also affect adipose tissue development, altering both the size of adipose cells and the lipolytic responsiveness of such cells.
Some of the altered physiological changes are
phenotypically expressed in response to dietary changes. Injecting a growth factor in ovo and then administering to the poultry after hatching a beta-adrenergic agonist has resulted in increased growth rate, more lean tissue deposition and decreased fat accretion. It is believed that other alterations of physiological development and response will result in improved immunological response. Additionally it is believed that reproductive performance and response to heat stress may be enhanced.
The growth factors which may be utilized are various substances which affect the growth and development of tissue, and which affect physiological responses. The preferred growth factors are growth hormones and the thyroid hormones, T3 and T4. The most preferred growth hormones are mammalian hormones, particularly ovine and bovine. Other possible growth factors include, but are not limited to other hormones (e.g. androgens), various steroids, and beta-adrenergic agonists such as
isoproterenol. The amount of growth factor used depends upon the type and size of the egg, the species of poultry, and the
type of growth factor used. For example, a range of 2.5 μg to 250 μg of growth homone is preferred for broilers with 250 μg most preferred, but 375 μg were administered to turkeys. For the thyroid hormones, the preferred amount for administration to broilers is .01 μg of T3 and 1.0 μg of T4. The preferred dosage was chosen because the amount is biologically effective and results in the highest rate of hatchability. These examples are not intended to limit the amounts of growth factor which may be used.
The growth factors are introduced into the eggs of the poultry during incubation. The growth factor may be introduced into the albumin or onto the chorioallantoic membrane. Those skilled in the art will appreciate that the site of introduction may also impact the necessary dosage. It is believed, although the inventors are not limited to this theory, that a smaller dosage will be effective if introduced onto the membrane. The preferred method of introduction is injection, although other methods such as spraying or dipping may be used if the growth factor is of sufficiently small size.
The preferred time window for injection is from and including the first day of the second half of the
incubation period up to and including the day of transfer from the incubator to the hatcher e.g. days 11 to 18 for broilers. This does preclude the injection of growth factor earlier in the incubation period. The incubation period is the time period from the day the eggs are placed in the incubator until they hatch. This includes the time period the eggs are in the hatcher. It is believed that the day the eggs are transferred from the incubator to the hatcher will be the most efficient day for introduction of the growth factor. Additionally, it appears that the hatchability rate is higher when the eggs are injected
later in the incubation period. The inventors also believe, but are not limited to this theory, that later introduction of growth factors may be more effective as certain tissues mature and become more active. For example, growth hormones may have a greater effect on body weight when injected after day 17 of the broiler
incubation period as the anterior pituitary becomes more active. At this later stage of incubation the growth factor must be injected onto the chorioallantoic membrane. It is preferred for efficiency purposes that the eggs be injected only one time, however it is not precluded that a number of injections may be utilized if necessary for the desired result. Some of the changes in growth development and
response, such as, but not limited to, lipolysis may be enhanced or triggered by administration of certain food additives to the maturing birds. A preferred class of additives is the beta-adrenergic agonists, in particular isoproterenol. While these compounds are characterized as food additives it is not precluded that they could be administered to the birds in a different fashion.
Additionally, the time period of administration and the amounts used may differ depending on the size and needs of the poultry species and the desired result.
Example 1; The affect of in ovo administration of growth hormone on broiler chickens. Administration of Growth Hormone
Two trials were conducted. In trial one, 100 fertile eggs from a commercial broiler were injected into the inferior end of the egg on day 11 of embryonic development with 100 μℓ of either vehicle alone as a control or vehicle containing 0.25, 2.5, 25 or 250 μg of ovine GH
(oGH). In trial 2, 600 eggs were injected with either vehicle, 2.5 or 250 μg of oGH on day 11 of the incubation. The vehicle consisted of the following: 0.03 M NaHCO3 (Sodium Bicarbonate) and 0.15 M NaCl (Sodium Chloride), pH 8.3. Injections were performed manually by first piercing a hole in the shell with an 18-gauge needle and then injecting the solution into the albumin using a 25-gauge needle. The injection holes were sealed with paraffin. Determination of Growth
And Feed Efficiencies
At hatch, chicks from both trials were wingbanded, weighed and sexed. Chicks were randomly assigned to floor pens according to sex and treatment. Birds were fed diets ad libitum. From 0 to 3 weeks of age the birds were fed a 22% protein, 3125 kcal energy starter diet. From 3 to 7 weeks of age the birds were fed a 19% protein, 3284 kcal energy grower ration. Body weight and feed consumption were recorded weekly. Shank length was measured at 3, 5 and 7 weeks of age.
Determination of Carcass Composition Birds chosen for carcass analysis were sacrificed by cervical dislocation at 7 weeks. Fat pad weights were recorded. Frozen carcasses (including feathers) were ground twice in a commercial meat grinder to obtain an homogenous mixture. Carcass fat content was determined by ether extraction and protein content was determined by the Kjedahl method. Methods of Analysis, Association of
Official Analytic Chemists, (1984).
Cellularity Studies
A sample of the fat pad of the broilers used for carcass analysis was obtained for adipose cellularity studies. Cells were prepared for sizing and counting by a modification of the procedure of Hirsh and Gallain, J. Lipid Res. 9:110-119 (1968). A 50-100mg sample of each fat pad was immediately placed in a 3% osmium tetroxide solution: 1.5 ml of 50 mM collidine, pH 7.4 plus 2.5 ml of 3% osmium tetroxide (diluted in the collidine buffer) for 72 hrs at 41°C for fixation. Following fixation, samples were washed with 0.9% saline (pH 7.4). Salinewashed samples were then incubated in 8 M urea for 48 hrs at 25°C. Adipocytes were then separated into two cell size ranges by sequential filtration through 240, 64 and 25 micron nylon screens. Debris collected on the 240 micron screen was discarded. Cells were washed from the remaining screens with 0.1% Triton X-100 in saline, pH 10. Cell size and number were determined by use of an electronic particle counter (Coulter Electronics, Inc., Model ZM) and channelizer (Coulter Electronics, Inc., Model C256). A 0.5 ml sample of the continuously stirring cell suspension was aspirated through a 400 micron aperature tube for cell sizing and counting. The distribution of cell diameters was calculated by totalling the sum of each 10-micron increment of cell sizes. Cell number was calculated using the specific density of fat (0.901) and the average cell volume. Average cell diameters and volumes were calculated using the standard geometrical formulas for a sphere.
In Vitro Lipolysis
Adipocytes were isolated from the abdominal fat pads of 7-week old broilers by a modification of the procedure of Rodbell, J. Biol. Chem. 239:375-380 (1964). Adipose
tissue was placed in warmed, oxygenated Krebs-Ringer bicarbonate buffer (KRB) containing 0.1% collagenase (Sigma, lot 126F-6735), 4% albumin and 1 mM glucose for approximately 45 min in a shaking waterbath at 41°C.
During this time, samples were gently agitated using wide-mouthed siliconized pasteur pipettes to mechanically disrupt clumps of connective tissue. Following enzymatic disruption of the tissue, the samples were washed 3x in the above KRB solution, collagenase-free. Samples were then filtered through a 240 micron nylon-mesh filter and counted as previously. Dilutions of 3.0 x 10 cells/ml were made and 0.5 ml of the cell suspension was added to 0.5 ml of warmed KRB buffer. Fifty microliters of buffer containing each lipolytic compound at specified concentrations were added to the appropriate culture tubes.
Following an 1 hr incubation at 41°C in a shaking waterbath, culture tubes were placed on ice and 1 ml of trichloroacetic acid was added immediately to stop the reaction and precipitate all protein. Samples were then centrifuged at 5°C for 20 min. The supernatant was decanted and extracted 3 times with 5 volumes of diethyl ether. Following the third extraction, the aqueous phase was stored at -20°C for subsequent glycerol analysis following the method of Buccolo and David, Clin. Chem. 19:476-482 (1973).
Statistical Analysis
Data were analyzed using the GLM procedure of the Statistical Analysis Systems Institute. Barr, A.J., J.H. Goodnight, J.P. Sall, W.B. Blair, and D.M. Chilko. SAS User's Guide. Raleigh, N.C. SAS Institute. 1979.
Analyses were conducted within sex and age groups testing for treatment effects. If significant treatment effects (P<.05) were observed, differences between means were determined using Duncan's multiple range test.
Determination of Growth
and Skeletal Development
Growth was determined as increase in body weight and skeletal development (which was determined by increase in shank length). In ovo administration significantly increased body weights of male broilers during the high protein phase of the grow out trial (0-3 wks). Body weights did not differ between control- and 2.5μg oGH-injected male broilers from 4-7 weeks of age. Males injected with 250μg oGH were significantly heavier than either of the other two treatments at 7 weeks of age.
(Table 1). Body weights of female broilers were not significantly altered. (Table 2). Similarly, the in ovo hormone treatment did not influence shank length of females, however injection of either 2.5 or 250μg of oGH resulted in significantly greater shank lengths in male broilers. (Figure 1). Measurements for shank length were taken at 7 weeks of age.
Table 1. Effect of in ovo ovine growth hormone injection on body weight (gms) and cumulative feed conversion ratios of male broilers from 1 to 7 weeks of age.
Dosage (μg/egg)
Age (weeks)* Vehicle 2.5 250
1 95 ± 2.8a 102 ± 1.7ab 103 ± 2.1b 2 256 ± 6.53 271 ± 3.4b 275 ± 5.8b
3 519 ± 7.5a 548 + 13.7ab 553 ± 10.7b
Feed/Gain 1.88 ± 0.07a 1.70 ± 0.06b 1.68 ± 0.04b
(week 0-3)
4 920 ± 12.5a 914 ± 8.9a 936 ± 9.6a
5 1346 ± 26.8a 1323± 23.4a 311 + ± 30.9a
6 1873 ± 14.1a 1884 ± 21.4a 1889 ± 12.7a
7 2411 ± 19.6a 2413 ± 17.0a 2464 ± 18.2b
Feed/Gain 2.36 ± 0.06a 2.36 ± 0.02a 2.30 ± 0.03a
(week 4-7)
*Values are means ± SEM. Means within age groups differ significantly (P<.05) if superscripts differ.
Feed to Gain Ratio
Feed to gain ratio determinations were made on the broilers. Male broilers injected with oGH exhibited significantly improved feed conversion ratios from hatch to 3 weeks of age. No difference in feed to gain ratios was observed during the 4-7 week period. (Table 1). The feed to gain ratio in female broilers was not
significantly altered during either time frame by
injection of oGH. (Table 2).
Table 2. Effect of in ovo ovine growth hormone injection on body weight (gm) and cumulative feed conversion ratios of female broilers from 1 to 7 weeks of age.
Dosage (μg/egg)
Age (weeks)* Vehicle 2.5 250
1 98 ± 1.8 98 ± 2.8 100 ± 2.2 2 247 ± 7.1 256 ± 6.9 259 ± 5.1
3 498 + 11.3 513 ± 12.8 497 ± 9.5
Feed/Gain 1.88 ±0.05 1.72 ±0.07 1.77 ± 0.03 (week 0-3)
4 834 ± 7.1 820 ± 16.6 823 ± 12.2
5 1152 ± 11.5 1172 ± 30.2 1159 ± 20.5
6 1579 ± 22.0 1578 ± 30.4 1588 ± 19.4
7 2024 ± 14.9 2022 ± 13.3 2024 ± 13.8
Feed/Gain 2.44 ± 0.05 2.44± 0.02 2.43 ± 0.02 (week 4-7)
*Values are means ± SEM. Means within age groups did not significantly (P<.05) differ.
Carcass Composition
In ovo hormone treatment did not statistically alter fat or protein content of the carcasses of either selected male or female broilers. (Table 3). Neither abdominal fat pad weights or fat pad as a percent of body weight was significantly altered in either of the sexes. (Table 4).
Table 3. Effect of in ovo administration of ovine growth hormone on percent carcass fat and protein of 7-week-old broilers.
Dosage* Male Female
(μg/egg)
Carcass Fat (%)
Vehicle 14.7 ± 0.5 15.7 ± 0.3
2.5 13.1 ± 0.5 15.5 ± 0.5
250 13.9 ± 0.6 16.4 ± 0.4
Carcass Protein (%)
Vehicle 16.0 ± 0.2 15.2 ± 0.2
2.5 15.8 ± 0.2 15.5 ± 0.2
250 15.5 ± 0.2 15.3 ± 0.2
*Values are means ± SEM. Means within sexes did not significantly (P>.05) differ.
Table 4. Effect of in ovo administration of ovine growth hormone on abdominal fat pad weights of 7-week-old broilers.
Dosage* Male Female
(μg/egg)
Fat Pad (gms)
Vehicle 42.3 ± 1.7 50.3 ± 1.7
2.5 47.5 ± 2.9 49.2 ± 2.2
250 45.1 ± 3.4 51.7 ± 2.8
Percent Fat Pad
Vehicle 1.77 ± 0.07 2.47 ± 0.08 2.5 1.90 ± 0.11 2.41 ± 0.12
250 1.79 ± 0.13 2.45 ± 0.11
*Values are means ± SEM. Means within sexes did not significantly (P>.05) differ.
Adipose Cellularity
Adipose cellularity data on selected broilers suggested that in ovo oGH administration altered adipose tissue development. Both male and female broilers treated with 250 μg of oGH exhibited larger adipocytes with a corresponding decrease in the number of cells per gram tissue, as determined at 7 weeks of age. (Table 5).
Birds treated with oGH had a greater proportion of fat cells from large volume classes than did the controls. (Figure 2).
Table 5. Effect of in ovo injection of ovine growth hormone on abdominal fat pad cellularity of broilers.
Mean Mean
Dosage* Adipocyte Number Adipocyte Volume Adipocyte Diameter
(μg/egg) (x 10 /10-1gm) (pL) (μm)
Male
Vehicle 8.7 ± 0.5a 63.1 ± 5.5a 44.9 ± 1.3
2.5 9.6 ± 2.6ab 63.4 ± 4.5a 45.1 ± 1.1ab
250 6.2 ± 0.6b 76.7 ± 4.5b 48.8 ± 1.2b
Female
Vehicle 11.6 ± 2.6a 58.9 ± 5.5a 44.3 ± 1.4a
2.5 8.9 ± 1.6ab 60.5 ± 5.7a 44.8 ± 0.9a
250 6.5 ± 0.8b 79.4 ± 3.8b 49.0 ± 0.7b
*Values are means ± SEM. Parameter means differ significantly (P<.05) within sexes if superscripts differ.
In Vitro Lipolysis Studies
An increase in adipocyte cell size suggests a decrease in lipolysis. Studies were done to determine if lypolysis is effected by in ovo injection of oGH, and if so how.
Glycerol release was used as an indicator of
lipolysis. Three compounds which induce lipolysis by differing mechanisms were tested: cholera toxin (enhances adenylate cyclase through a receptor-independent
mechanism), theophylline (inhibits phosphodiesterase), and dibutyryl cAMP ( dcAMP - - not degraded by phosphodiesterase). A combination of cholera toxin and theophylline was also used. The results are shown in Figure 3.
The adipocytes exhibited decreased sensitivity to cholera toxin or theophylline-induced lipolysis and increased lipolytic response to dcAMP in vitro, suggesting that oGH injected in ovo decreased lipolysis either by diminishing adenylate cyclase activity or enhancing phosphodiesterase activity. The combined addition of cholera toxin and theophylline significantly improved the lipolytic response over that of the addition of either compound alone, further implicating high phosphodiesterase activity in adipocytes of broilers injected with oGH in ovo.
Example 2: Determination of Growth and Skeletal
Development of Broilers in Response to Vatious Sources of Mammalian GHs.
Four hundred fertile eggs from a commercial broiler strain were injected with either vehicle (control injection) or 250 μg of either bovine or porcine GH on day 11 of incubation. (See Example 1 for basic procedures.) Growth was determined as an increase in body weight and skeletal development was determined by an increase in shank length. Males injected with bGH were significantly heavier than control males, at 3, 5 and 7 weeks (Table 6). Shank length was significantly greater in bGH-treated males versus controls (Table 7).
Table 6. Effect of in ovo administration of mammalian GHs on body weights of male broilers.
Body Weight (gm)1
Age Control Bovine Porcine
(weeks)
0 39 ± 0.2a 39 ± 0.4a 39 ± 0.3a 1 121 ± 1.2a 121 ± 1.8a 123 ± 1.6a 3 597 ± 4.7a 615 ± 6.8b 600 ± 5.9ab
5 1277 ± 9.3a 1345 ±14.2b 1296 ±12.6a
7 1869 ±10.6a 1966 ±18.7b 1901 ±16.6a 1Treatment means ± SEM significantly (P>.05) differ within ages if superscripts differ.
Table 7. Effect of in ovo administration of mammalian GHs on carcass parameters of male broilers at 7 weeks of age.
Parameter Control Bovine Porcine
Abdominal Fat 27.1 ± 1.39a 30.5 ± 1.98a 32.3 ± 1.46a
Pad Weight (gms)
Shank Length 61 ± 0.56a 63 ± 0.53b 60 ± 0.46a (mm)
1Parameter means ± SEM significantly (P<.01) differ if superscripts differ.
Example 3: Summary of Trials Examining the Effects of In Ovo GH Administration on Seven Week Body Weights of Broilers.
Four trials (See Example 1 for general procedures) have been conducted to assess the influence of in ovo GH (250 μg/egg at 11 days of incubation) administration on subsequent growth of broilers. In each trial, in ovo GH resulted in improved 7 week body weights of male broilers (Table 8).
Table 8. In ovo mammalian growth hormone administration
significantly improves 7 week body weights of male broilers.
Weight (gms)
Trial 1
Control 2217± 76
GH* 2408 ± 59
(P<.05)
Trial 2
Control 2411 ± 20
GH* 2464 ± 18
(P<.05)
Trial 3
Control 2010 ± 22
GH* 2068 ± 22
(P<.04)
Trial 4
Control 1869 ± 11
GH** 1966 ± 19
(P<.0001)
*Ovine GH (250 μg/egg) was injected into the inferior end of fertile broiler eggs at day 11 of embryogenesis.
**Bovine GH (250 μg/egg) was injected into the inferior end of fertile broiler eggs at day 11 of embryogenesis.
Example 4 : Determination of Growth and Skeletal
Development of Turkeys In Response to
In Ovo Administration of oGH.
Six hundred and eighty fertile eggs from a commercial turkey strain were injected in the inferior end with either vehicle or 375 μg oGH on day 15 of incubation. Injections were performed manually by first piercing a hole in the shell with an 18-gauge needle and then injecting the solution into the albumin using a 25-gauge needle. The injection holes were sealed with paraffin. At hatch, poults were wingbanded, weighed and sexed.
Birds were randomly assigned to floor pens according to sex and treatment and were fed conventional diets.
Growth was determined as increase in body weight.
Preliminary results indicate that the in ovo
administration of oGH significantly increased hatch and 10 week body weights of females (Table 9). Numerical differences among female treatment groups occurred at all other ages. Body weights of male turkeys were not significantly altered.
Table 9. Effect of in ovo ovine growth hormone injection on body weight (gms of turkeys from hatch of 10 weeks of age.
Dosage (μg/egg)
Age Vehicle 375
(weeks)*
Male
0 62.0 ± .6a 61.7 ± .7a
1 132.1 ± 1.9a 133.2 ± 2.1a
3 574.5 ± 9.6a 571.9 ± 9.2a
5 1430.1 ± 19.5a 1421.5 ± 20.0a
10 5198.8 ± 72.4a 5265.9 ± 57.0a
Female
0 60.5 ± .5b 62.0 ± .5a
1 120.8 ± 1.9a 125.7 ± 1.8a
3 518.9 ± 7.4b 522.2 ± 8.4a"
5 1236.8 ± 16.8a 1275.3 ± 18.8a
10 4350.4 ± 55.2b 4535.7 ± 62.7a
* Values are means + SEM. Means within age and sex differ significantly (P<.05) if superscripts differ.
Example 5: Effect of In Ovo Administration of Thyroid Hormone On Lipolytic Responsiveness. Eggs (N=100/treatment) were incubated and injected in the inferior end with 100 μℓ, of phosphate buffered saline (pH 7.4) containing 0.1% BSA or .01 μg T3 (Sigma). At hatch, birds were sexed, wingbanded, weighed and randomly assigned to floor pens by sex and treatment.
Body weights and feed consumption were recorded weekly and at 35 and 49 days of age adipocytes were isolated from abdominal fat pads by a modification of the method of Rodbell (1964). Fat pads from four birds per in ovo treatment were excised and rinsed in warm 0.9% saline (pH 7.4) to remove free lipid droplets. Fat tissue was then minced and a 4 gram sample from each in ovo treatment group placed into Kreb's Ringer bicarbonate buffer containing 0.1%
collagenase (Sigma, lot #126F-6735), 4% albumin, and 1 mM of glucose for 45 minutes in a shaking water bath at 41°C. Following enzymatic digestion, samples were washed three times in oxygenated collagenase-free Krebs-Ringer bicarbonate buffer containing 4% albumin and 1 mM glucose (pH 7.4). Adipocytes were then filtered through a 243 micron nylon-mesh filter to remove debris and cell clumps and counted by use of an electronic particle counter (Coulter, model ZM). Dilutions of 3-4 x 10 cells per ml were made and 0.5 ml of the cell dilution was added to 0.5 ml of warmed Krebs-Ringer bicarbonate buffer (pH
7.4). Fifty μℓ of a specific lipolytic agent was added to each culture tube. Treatments consisted of 0, 10, 100, 1000, and 10,000 ng/ml glucagon; 0, 1 and 10 mM theophylline; 0, 5, 10 and 20 μg of cholera toxin; or 10 mM of dibutyrl cAMP.
Following a one-hour incubation at 41°C in a shaking water bath, culture tubes were placed on ice and 1 ml of 10% trichloroacetic acid immediately added to terminate the culture. The supernatant was removed and extracted three times with 5 volumes of diethyl ether. The aqueous phase was stored at -20°C for subsequent glycerol
analysis (Bucolo and David, 1973).
Data were analyzed using the GLM procedure of
Statistical Analysis Systems Institute (SAS, 1982).
Significant treatment effects (P<.05) were further separated using Duncan's multiple range test (Duncan, 1955). Effect On In Vitro Lipolysis
Glycerol release was used as an indicator of
lipolysis. Concentrations of 1 and 10 mM of theophylline significantly increased lipolysis at 35 and 49 days of age in cells of T3-treated birds (Table 10). Adipocytes from control birds exhibited significant increases in lipolysis at concentrations of 10 mM of theophylline only (Table 10). The addition of 2 or 10 mM dcAMP to
adipocytes isolated from both control and T3-treated birds resulted in significant increases in glycerol release at both 35 and 49 days (Table 11). Glycerol release, however, was significantly greater in response to 10 mM dcAMP in cells from T3-treated birds as compared to controls (Table 11). No significant differences in glycerol release in response to cholera toxin were observed between control of T3-treated birds at 35 or 49 days of age (Table 12). Cells from both in ovo
treatments responded maximally to the same dosage of cholera toxin (5 μg/ml). Increased lipolytic sensitivity to glucagon was seen in adipocytes from T3-treated birds at both 35 and 49 days of age as compared to controls,
although maximal stimulation of glycerol release was not statistically different.
Table 10. In vitro lipolytic response of adipocytes isolated from broilers injected in ovo with T3 to theophylline.
Theophylline Control T3
(mM)
35-Days of Age2
0 1.22 ± 0.09a 1.25 ± 0.07a
1 1.55 ± 0.23a 2.40 ± 0.35b
10 1.83 ± 0.07b 2.60 ± 0.37b
49-Days of Age"
0 1.90 ± 0.20a 2.02 ± 0.65a
1 1.95 ± 0.58a 4.15 ± 0.23b
10 3.72 ± 0.09b 4.04 ± 0.25b
Means within in ovo treatments significantly differ
(P≤.05) from basal if superscripts differ.
2Glycerol release (μg/1.8 x 105 cells).
3Glycerol release (μg/2 x 105 cells).
Table 11. In vitro lipolytic response of adipocytes isolated from broilers injected in ovo with T3 to dibutryl cAMP (dcAMP).
dcAMP1 Control T3
(mM)
35-Days of Age2
0 0.86 ± 0.05a 0.98 ± 0.03a
2 2.03 ± 0.20b 2.08 ± 0.08b
10 1.79 ± 0.18b 2.55 ± 0.16b
49-Days of Age3
0 1.90 ± 0.20a 2.02 ± 0.65a
2 6.42 ± 0.46b 5.84 ± 0.65b
10 7.60 ± 0.50b 8.19 ± 0.24c
1Means within in ovo treatments significantly differ
(P≤.05) from basal if superscripts differ.
2Glycerol release (μg/1.8 x 105 cells).
3Glycerol release (μg/2 x 105 cells).
Table 12. In vitro lipolytic response of adipocytes isolated from broilers injected in ovo with T3 to cholera toxin.
Cholera toxin1 Control T3
(μg/ml)
35-Days of Age2
0 0.86 ± 0.05a 0.98 ± 0.03a
5 1.38 ± 0.18b 1.61 ± 0.06b
10 1.72 ± 0.17b 1.62 ± 0.14b
20 1.32 ± 0.12b 1.26 ± 0.08b
49-Days of Age3
0 1.90 ± 0.20a 2.02 ± 0.23a
5 3.99 ± 1.34b 5.69 ± 1.02b
10 4.57 ± 0.76b 3.76 + 1.81ab
20 3.03 ± 0.93b 4.91 ± 0.62b
Means within in ovo treatments significantly differ
(P≤.05) from basal if superscripts differ.
2Glycerol release (μg/1.8 x 105 cells).
3Glycerol release (μg/2 x 105 cells).
Example 6 : The effect of in ovo injection of thyroid hormone and feeding of dietary betaadrenergic agonist on broiler chickens.
Two thousand Hubbard x Hubbard broiler eggs were conventionally incubated. At day 11 of incubation, eggs were candled and fertile eggs were injected into the albuminous end of the egg using a 25-gauge needle with a 3mm needle guard. Treatments consisted of 0.1 ml of either 0.01 μg of T3 or 1.0 μg of T4 in phosphatedbuffered saline (PBS) or PBS alone. At day of hatch, birds were sexed, wingbanded, weighed and randomly assigned to floor pens by treatment group and sex. For the first three weeks, the birds were fed a conventional broiler starter diet (22% protein, 3125 kcal/kg) ad libitum. From 3 to 8 weeks of age, a conventional broiler grower diet (19% protein, 3285 kcal/day) was fed ad libitum. Both starter and grower diets contained 1 ppm isoproterenol (ISP).
Feed consumption and body weights were recorded weekly throughout the grow-out trial. At the conclusion of experiment two, 10 randomly selected birds from each in ovo treatment group and sex were selected at 8 weeks of age and killed via cervical dislocation. Abdominal fat pads were removed and weighed and a sample was taken for cellularity studies. Carcasses were frozen at -20°C for subsequent carcass analysis. (See Example 1 and 5 for basic procedures).
Effect On Growth
Body weights of male broilers injected in ovo with T3 and fed 1 ppm ISP in the feed were significantly greater than control male weights from 5 to 7 weeks of
age (Figure 4). The T4-treated males exhibited
significantly lower body weights than control or T3-treated males from 1 to 4 weeks of age, however, by 7 weeks of age, body weights of T4-treated males were not significantly different from control.
Body weights of female broilers did not
significantly differ between treatment groups from 2 to 6 weeks of age. As shown in Figure 5, T3-treated females exhibited significantly greater body weights than T4-treated birds at week one. At week 7, body weights of T4-treated females were significantly less than weights of control females. Effect On Feed Conversion
No consistent differences in feed conversion ratios were observed for either male or female broilers due to in ovo hormone administration (Table 13). Feed
conversion ratios of male T3-treated birds were
significantly improved versus control at week 5; whereas the feed to gain ratio of T4-treated male birds were significantly lower than control at week 1. Feed
conversion ratios of T4-treated females were
significantly increased at week 7 in comparison to control or T3-treated females.
Effect On Carcass Composition A significant increase in carcass protein deposition was observed at 8 weeks of age in T3-treated male
broilers fed 1 ppm isoproterenol in comparison to control or T4-treated males. There were no significant treatment differences in carcass protein of female broilers (Figure 6).
Although a trend (P<0.1) was observed for the T3-treated broilers to exhibit less carcass fat than controls (Figure 7), no significant differences in percent lipid at 8 weeks of age were observed due to in ovo treatment for either male or female broilers.
Effect On Adipose Cellularity
Abdominal fat pad weights at 7 weeks of age
expressed as a percent of body weight are shown in Figure 8. In ovo injection of T4 resulted in a significant reduction in fat pad weights when expressed as a percent of body weight in comparison to controls.
TABLE 13
Feed Conversion of In Ovo Thyroid
Hormone Injection and Dietary Isoproterenol.
Feed Conversion
MALE
Week Control T3 T4
1 1.89 + 0.09 1.76 + 0.06 1.66 + 0.07
2 1.97 + 0.06 1.91 + 0.04 1.87 + 0.07
3 2.08 + 0.06 1.97 + 0.03 1.97 + 0.06
4 1.82 + 0.03 1.80 + 0.02 1.79 + 0.04
5 2.47 + 0.08 2.16 + 0.08 2.23 + 0.08
6 2. 67 + 0.08 2.72 + 0.06 2.64 + 0.04
7 3.32 + 0.27 3.18 + 0.16 2.73 + 0.08
FEMALE
1 1.82 + 0.06 1.78 + 0.06 1.71 + 0.10
2 1.98 + 0.03 2.02 + 0.04 1.94 + 0.07
3 1.83 + 0.22 2.00 + 0.38 2.01 + 0.08
4 1.83 + 0.02 1.84 + 0.02 1.83 + 0.03
5 2.39 + 0.06 2.61 + 0.13 2.27 + 0.04
6 2.86 + 0.06 2.84 + 0.06 3.01 + 0.13
7 3.11 + 0.06 3.11 + 0.13 3.67 + 0.24
Means within week s differ (P<.05) if superworipts differ
Claims
1. A method of enhancing the physiological development and responses of poultry comprising the steps of: incubating fertilized eggs of the desired poultry species; introducing a biologically effective amount of
growth factor into the incubating fertilized egg; and thereafter allowing the altered poultry to hatch and mature.
2. The method of claim 1 comprising the added step of administering to the hatched poultry a biologically effective amount of a beta-adrenergic agonist.
3. The method of claim 2 wherein the beta-adrenergic agonist is isoproterenol.
4. The method of claim 1 or 2 wherein the growth factor is injected.
5. The method of claim 1 or 2 wherein the growth factor is a growth hormone.
6. The method of claim 5 wherein the growth factor is mammalian growth hormone.
7. The method of claim 6 wherein the growth factor is ovine growth hormone.
8. The method of claim 6 wherein the growth factor is bovine growth hormone.
9. The method of claim 1 or 2 wherein the growth factor is a thyroid hormone.
10. The method of claim 1 or 2 wherein the growth factor is isoproterenol.
11. The method of claim 1 or 2 wherein the step of injecting the eggs occurs during the time period from and including the first day of the second half of the
incubation period up to and including the day the eggs are transferred from the incubator to the hatcher.
12. The method of claim 1 or 2 wherein the step of injecting the eggs occurs on the first day of the second half of the incubation period of the egg.
13. The method of claim 1 or 2 wherein the step of injecting the eggs occurs on the day the eggs are
transferred from the incubator to the hatcher.
14. The method of claim 1 or 2 wherein the poultry are chickens.
15. The method of claims 1 or 2 wherein the poultry are turkeys.
16. A method of enhancing the growth and meat production of poultry comprising the steps of: incubating fertilized eggs of the desired poultry species; injecting a biologically effective amount of growth factor selected from the group consisting of ovine, bovine, or porcine growth hormone, or T3 or T4 into the incubating fertilized eggs during the time period from and including the first day of the second half of the incubation period up to and including the day the eggs are transferred from the incubator to the hatcher; and thereafter allowing the altered poultry to hatch and mature.
17. The method of claim 16 comprising the added step of administering to the hatched poultry a biologically active amount of a beta-adrenergic agonist.
18. The method of claim 17 wherein the beta-adrenergic is isoproterenol.
19. The method of claim 16 or 17 wherein the eggs are injected on the day the eggs are transferred from the incubator to the hatcher.
20. The method of claim 16 or 17 wherein the step of injection occurs on the first day of the second half of the incubation period of the eggs.
21. The method of claim 16 or 17 wherein the poultry are chickens.
22. The method of claim 16 or 17 wherein the poultry are turkeys.
23. A method of enhancing the growth and meat production of chickens comprising the steps of: incubating fertilized chicken eggs; injecting a biologically effective amount of ovine growth hormone into the albumin of the incubating fertilized eggs on the first day of the second half of the
incubation period of the eggs; and thereafter allowing the altered chickens to hatch and mature.
24. A method of enhancing the growth and meat production of chickens comprising the steps of: incubating fertilized chicken eggs; injecting a biologically effective amount of thyroid hormone into the albumin of the incubating fertilized eggs; on the first day of the second half of the
incubation period of the eggs; and thereafter allowing the altered chickens to hatch and develope.
25. The method of claim 23 or 24 comprising the added step of administering to the chickens a biologically active amount of isoproterenol.
26. A product comprising poultry produced by the method as in any of claims 1, 2, 3, 16, 17, 18, 23 or 24.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30811389A | 1989-02-08 | 1989-02-08 | |
US308,113 | 1989-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990009188A1 true WO1990009188A1 (en) | 1990-08-23 |
Family
ID=23192608
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1989/005131 WO1990009188A1 (en) | 1989-02-08 | 1989-11-16 | In ovo administration of growth factors alters physiological development and response of poultry |
PCT/US1990/000740 WO1990009190A1 (en) | 1989-02-08 | 1990-02-08 | In ovo administration of growth factors alters physiological development and response of poultry |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/000740 WO1990009190A1 (en) | 1989-02-08 | 1990-02-08 | In ovo administration of growth factors alters physiological development and response of poultry |
Country Status (2)
Country | Link |
---|---|
AU (2) | AU5166590A (en) |
WO (2) | WO1990009188A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998014781A1 (en) * | 1996-10-04 | 1998-04-09 | Embrex, Inc. | Method of sorting birds in ovo |
CN103719018A (en) * | 2014-01-03 | 2014-04-16 | 江苏省家禽科学研究所 | Method for improving growth speed of ducks in embryonic phase |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4986393A (en) * | 1992-08-19 | 1994-03-15 | Massey University | Methods for effecting a prolonged reduction in measurable fat content and medicaments for use therein |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0167381A2 (en) * | 1984-07-05 | 1986-01-08 | Embrex Inc. | Increasing the efficiency of poultry production |
-
1989
- 1989-11-16 AU AU51665/90A patent/AU5166590A/en not_active Abandoned
- 1989-11-16 WO PCT/US1989/005131 patent/WO1990009188A1/en unknown
-
1990
- 1990-02-08 AU AU51026/90A patent/AU5102690A/en not_active Abandoned
- 1990-02-08 WO PCT/US1990/000740 patent/WO1990009190A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0167381A2 (en) * | 1984-07-05 | 1986-01-08 | Embrex Inc. | Increasing the efficiency of poultry production |
Non-Patent Citations (6)
Title |
---|
Federation of American Societies for Experimental Biology, 72nd Annual Meeting, Las Vegas, Nevada, 1-5 May 1988, A.M. LEE et al.: "in Ovo Growth Hormone Injection Effects Lipid Metabolism in Broilers" see page A1623; Abstract 7705 * |
Federation of American Societies for Experimental Biology, 72nd Annual Meeting, Las Vegas, Nevada, 1-5 May 1988, E.J. WILLINGHAM et al.: "Effects of in Ovo Trillodothyronine Injection on Lipid Metabolism in Broilers", see page A1623; Abstract 7706 * |
Federation of American Societies for Experimental Biology, 73rd Annual Meeting, New Orleans, Louisiana, 19-23 March 1989, S.F. GREENCE et al.: "In Ovo Administration of Triiodothyronine Enhances Broiler Responsiveness to a Dietary beta-Adrenergic Agonist.", see page A1257; Abstract 5994 * |
Growth Development & Aging, Volume 53, 1989, P.S. HARGIS et al.: "In Ovo Growth Hormone Alters Growth and Adipose Tissue Development of Chickens", pages 93-99 * |
Poultry Science, Volume 67, Supplement 1, 1988 P.S. HARGIS et al.: "Effect of Dietary or in Ovo Isoproterenol Administration on Growth and Fattening of Broilers", see page 95 * |
The Journal of Experimental Zoology, Volume 232, 1984, Alan R. Liss, Inc., D.B. KING et al.: "Thyroidal Influence on Body Growth", pages 453-460 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998014781A1 (en) * | 1996-10-04 | 1998-04-09 | Embrex, Inc. | Method of sorting birds in ovo |
US6506570B1 (en) | 1996-10-04 | 2003-01-14 | Embrex, Inc. | Method of sorting birds in ovo |
US6989238B2 (en) | 1996-10-04 | 2006-01-24 | Embrex, Inc. | Method of sorting birds |
CN103719018A (en) * | 2014-01-03 | 2014-04-16 | 江苏省家禽科学研究所 | Method for improving growth speed of ducks in embryonic phase |
Also Published As
Publication number | Publication date |
---|---|
AU5166590A (en) | 1990-09-05 |
AU5102690A (en) | 1990-09-05 |
WO1990009190A1 (en) | 1990-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Domm et al. | Endocrine factors controlling erythrocyte concentration in the blood of the domestic fowl | |
Dalrymple et al. | A repartitioning agent to improve performance and carcass composition of broilers | |
Andrews et al. | Influence of thiouracil and stilbestrol on growth, fattening, and feed efficiency in broilers | |
Hoskins | The growth of the body and organs of the albino rat as affected by feeding various ductless glands (thyroid, thymus, hypophysis and pineal) | |
Rosales | Managing stress in broiler breeders: a review | |
Thayer et al. | Fattening chickens by feeding estrogens | |
Morris et al. | The induction of ovulation in starving pullets using mammalian and avian gonadotropins | |
Zhong et al. | Effect of full feed and early feed restriction on broiler performance, abdominal fat level, cellularity, and fat metabolism in broiler chickens | |
Edwards Jr et al. | Effect of short fasts on the development of tibial dyschondroplasia in chickens | |
Breitenbach et al. | Effect of incubation and brooding on fat, visceral weights and body weight of the hen pheasant (Phasianus colchicus) | |
Detwiler et al. | The influence of thiouracil and stilbestrol on broiler quality | |
Wheeler et al. | The Value of Thyroprotein in Starting, Growing and Laying Rations: I. Growth, Feathering and Feed Consumption of Rhode Island Red Broilers | |
Nalbandov | Endocrine control of physiological functions | |
Zainur et al. | Recombinant growth hormone in growing lambs: effects on growth, feed utilization, body and carcass characteristics and on wool growth | |
WO1990009188A1 (en) | In ovo administration of growth factors alters physiological development and response of poultry | |
Langslow et al. | Alterations with age in composition and lipolytic activity of adipose tissue from male and female chickens | |
Berg et al. | Effect of photoperiod on the response of developing pullets to different nutritional treatments | |
US20170252386A1 (en) | Method for feeding poultry | |
MITCHELL | The effects of avian gonadotrophin precipitate on pituitary-deficient hens | |
US20150037439A1 (en) | Phytogenic nutraceutical composition and methods of use thereof | |
Merkley et al. | Adipose tissue deposition and cellularity in cimaterol-treated female broilers | |
Fiems et al. | A note on the effect of feeding cimaterol on some endocrinological parameters and growth in different types of finishing beef bulls | |
McCartney et al. | Reproductive performance of turkey females as affected by grower and pre-breeder diets | |
Davis et al. | Finishing market turkeys with estrogens | |
Crouch et al. | Effect of physical feed restriction during rearing on Large White turkey breeder hens: 3. Body and carcass composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE ES FR GA GB IT LU ML MR NL SE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |